Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure by Gabriela Molina O et al.
CASE REPORT
Transthyretin cardiac amyloidosis: an under-diagnosed
cause of heart failure
Gabriela Molina O, MD
1*, Daniel Judge, MD
2, Wayne Campbell, MD
3,
Harjit Chahal, MD
4 and Marc Mugmon, MD, FACC
5
1Department of Internal Medicine, Medstar Union Memorial Hospital, Baltimore, MD, USA;
2Center for
Inherited Heart Disease, Johns Hopkins University, Baltimore, MD, USA;
3Department of Internal Medicine,
Division of Infectious Diseases, Medstar Union Memorial Hospital, Baltimore, MD, USA;
4Department of
Internal Medicine, Medstar Union Memorial Hospital, Baltimore, MD, USA;
5Department of Cardiology,
Medstar Union Memorial Hospital, Baltimore, MD, USA
Introduction: Cardiac amyloidosis is the most common cause of infiltrative cardiomyopathy and is associated
with a poor prognosis. Transthyretin cardiac amyloidosis, particularly the type caused by the mutation that
replaces the amino acid valine with the amino acid isoleucine at position 122 (Val122Ile), is most common
among African- Americans above 65 years of age. Evidence suggests that this mutation is an important,
though under-diagnosed, cause of heart failure in this population.
Case presentation: A 74-year-old African American male with a diagnosis of non-ischemic cardiomyopathy
for several years, presented with gradually worsening dyspnea on exertion and lower extremity edema. There
is no known cardiac disease in his family. An echocardiogram was done showing a decrease in ejection
fraction to 30% from 45% in the span of a year. An endomyocardial biopsy analysis identified transthyretin
amyloid with the Val122Ile mutation, confirming the diagnosis of familial transthyretin cardiomyopathy.
Discussion: Systemic amyloidosis is a group of diseases caused by the deposition of an abnormally folded,
insoluble protein that can accumulate in multiple organs causing progressive and irreversible dysfunction.
The mutations that most commonly induce variant transthyretin cardiac amyloidosis are Val122Ile, Val30Met
and Thr60Ala. The Val122Ile mutation has been found to be present in 34% of the African American/
Caribbean population.
Conclusions: Familial amyloid cardiomyopathy is an uncommonly recognized cause of heart failure in the
population, and patients may wait several years before accurate diagnosis, risking additional significant
irreversible deterioration. Patients that meet the high-risk profile criteria  male gender, age 65 years and older,
heart failure symptoms, symmetric left ventricular (LV) hypertrophy, and moderately depressed LV function 
should likely undergo additional testing for cardiac amyloidosis.
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S
ystemic amyloidosis is a group of diseases caused
by an abnormally folded insoluble protein that
can accumulate in multiple organs, leading to their
progressive dysfunction. The particular precursor protein
that misfolds defines the amyloid type and predicts
the patient’s clinical course (1). Early identification and
accurate classification of the type of amyloid are keys to
establish the prognosis and treatment, given that several
novel therapies are on the near horizon.
Cardiac amyloidosis is the most common cause of infil-
trative cardiomyopathy, and compared with other etiolo-
gies (such as sarcoid and hemochromatosis) is associated
with aworse prognosis (2). In general, amyloid infiltration
of the heart causes both mechanical and electrochemical
disruption of cardiac function, manifesting itself as ven-
tricularthickeningandrestrictiveabnormalities,withboth
diastolic and systolic dysfunction. All cardiac tissues are
susceptible, and conduction and valvular abnormalities
as well as vascular infiltration (1) can lead to death.
There are two types of amyloid that commonly infil-
trate the heart. The first is Immunoglobulin light chain
(AL or primary amyloidosis). The second is transthyretin
amyloidosis (TTR), which includes both mutant or
variant transthyretin (familial amyloid cardiomyopathy
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genetic disease caused by wild-type transthyretin (senile
systemic amyloidosis) (1).
Among the variants of TTR that affect the heart, the
one with the valine-to-isoleucine substitution at position
122 (Val122Ile) is particularly prevalent among African
Americans above 65 years of age (3). Evidence suggests
that this mutation is an important, though under-diagnosed,
cause of heart failure in the elderly black community,
with virtually undetectable prevalence in the white popu-
lation (4).
Case presentation
A 74-year-old African American male with history of
cardiomyopathy was hospitalized with progressive dys-
pnea on exertion and lower extremity edema. One week
prior to admission he had worsening lower extremity
edema, orthopnea, and paroxysmal nocturnal dyspnea
unresponsive to an increase in his usual dose of oral
furosemide, over which time he noted an 8-pound weight
gain. NT-proBNP was 8,080 pg/ml, and troponin I was
0.151 ng/ml. Past medical history includes Type 2 diabetes
mellitus, hypertension, chronic kidney disease, dyslipide-
mia, benign prostatic hyperplasia, sleep apnea, cataracts,
glaucoma, right and left carpal tunnel syndrome status
post release surgery 3 and 8 years ago, respectively, and
several surgeries for stenosing tenosynovitis.
There was no family history of heart disease. There
was a remote history of smoking, and he used alcohol
rarely, and denied using illicit drugs. Medications included
aspirin, valsartan, furosemide, metolazone, simvastatin,
spironolactone, metoprolol, glipizide, and latanoprost
ophthalmic.
On physical examination the patient was not in
distress. Blood pressure was 97/61, respiratory rate was
22 per minute, heart rate was 69 bpm, and SatO2 was
100% on room air. Significant jugular venous disten-
tion was noted. Minimal bibasilar crackles were present.
Point of maximal impulse (PMI) was displaced laterally,
but no murmurs or gallops were noted. Abdomen was
slightly distended, without organomegaly or ascites, and
3 pitting edema extended to the thighs and scrotum.
Electrocardiogram (EKG) showed low voltage in limb
leads, Q waves compatible with prior inferior infarction,
left anterior fascicular block, and prolonged QTc. Chest
x-ray revealed no infiltrates or cardiomegaly.
Non-ischemic cardiomyopathy was diagnosed 3 years
prior to this admission. Cardiac catheterization revealed
no coronary artery disease, mild global left ventri-
cular (LV) hypokinesis, and ejection fraction of 45%.
He had two prior admissions to the hospital for con-
gestive heart failure exacerbation, each time responding
to intravenous diuretics. A recent echocardiogram dem-
onstrated a drop in ejection fraction to 30% with
global hypokinesis, with marked echogenicity of the LV
myocardium (Fig. 1). Pulmonary artery systolic pressure
was estimated to be 55 mmHg.
Evaluation for amyloidosis revealed serum protein
electrophoresis (SPEP) to be negative for monoclonal
gammopathy. His serum free kappa light chain was twice
the normal level, and there was very mild serum lambda
elevation. Immunofixation electrophoresis revealed no
evidence of monoclonal gammopathy. An abdominal
fat padbiopsy waspositive for amyloiddeposits by Congo
red staining and the presence of apple green birefringence
under polarized light. Cardiac MRI demonstrated diffuse
LV hypertrophy and significant infiltrative process invol-
ving the entire myocardium (Figs. 2 and 3).
Fig. 1. A four-chamber apical view echocardiogram showing
bi-atrial dilatation, valve thickening, thick ventricular walls,
and interventricular septum with speckled appearance.
Fig. 2. (AD) Inversion sequence trying to determine
optimal inversion time to assess for late gadolinium enhance-
ment. Inversion time (TI)97.5, 125, 152.5, and 180 ms,
respectively. There is no optimal delineation of myocardial
nulling relative to the myocardial blood pool. (C) TI of
152.5 demonstrate areas of increased signal within the
myocardium which have increased relaxivity related to the
blood pool which is opposite normal relaxation parameters
and suggestive of diffuse inﬁltration of the myocardium,
characteristic of amyloidosis.
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(despite the absence of detectable monoclonal gammo-
pathy), endomyocardial biopsy was performed and mass
spectrometry analysis identified transthyretin amyloid
with the Val122Ile mutation, confirming the diagnosis
of familial amyloid cardiomyopathy. TTR genetic testing
showed that he is heterozygous for this mutation.
Treatment with aggressive intravenous diuretics was
started. Weight decreased and edema resolved. At dis-
charge, the patient was euvolemic but he still had NYHA
class III symptoms. His beta blocker and angiotensin II
receptor blocker were discontinued and he remained on a
high dose of furosemide.
Discussion
Systemic amyloidosis is a group of diseases caused by the
deposition of an abnormally folded, insoluble protein
that can accumulate in multiple organs causing progres-
sive and irreversible dysfunction. More than 27 different
precursor proteins have the propensity to form amyloid
fibrils (5). TTR is caused by a misfolding in the hepatic-
derived transthyretin in to amyloid and is the most
common hereditary amyloidosis.
The mutations that most commonly induce variant
TTR cardiac amyloidosis are Val122Ile, Val30Met, and
Thr60Ala. Similarly to our patient, most individuals
developalate-onset cardiacamyloidosisandtheVal122Ile
mutation has been found to be present in 34% of the
African American/Caribbean population (4, 6). The allele
frequency of Val122Ile in the United States is 0.44%
for Caucasians and 0% for Hispanics (4).
Diagnosis requires identification of pathologic amyloid
deposition. This can be done by Congo red staining,
with the characteristic apple green birefringence under
polarized light. The particular precursor protein can be
identified by immunohistochemical staining, immunogold
electron microscopy, or mass spectrometry, which confers
the greatest sensitivity and specificity for amyloid typing
(7, 8).
An abdominal fat biopsy can identify amyloid deposits
in 70% of those with variant TTR such as Val122Ile
disease (9), but cardiac biopsy it is the gold standard for
the diagnosis of amyloid cardiomyopathy.
Echocardiography remains the most useful non-
invasive imaging modality for identifying and monitoring
this disease (1). There are no established echocardio-
graphic criteria for TTR disease; most of the available
data are based on the AL population. In general, amyloid
infiltration in the heart presents as thick-walled ventricle
with a speckled appearance of the myocardium, dimin-
ishedLV chambervolume, valve thickening, atrialenlarge-
ment, and signs of elevated filling pressures caused by
diastolic heart failure (1). Among patients with TTRwith
cardiac involvement, a LV ejection fraction of less than
50% is associated with reduced survival (10).
Increased wall thickness remains a major diagnostic
criterion of cardiac amyloidosis. The combination of LV
wall thickening with a low-voltage EKG is suggestive of
an infiltrative cardiomyopathy, and has a sensitivity
of (7279%) and specificity (91100%) for amyloidosis
(11).
Cardiac MRI with gadolinium enhancement may play
an important role in differentiating and identifying
cardiac amyloidosis, as it has been proposed that it can
distinguish between AL amyloidosis and TTR with good
diagnostic accuracy (12).
The overall survival of TTR amyloidosis is signifi-
cantly better than AL with cardiac involvement (6).
Cardiac AL amyloidosis has a high mortality with a life
span of 612 months from diagnosis (13). In contrast, it
has been reported that hereditary TTR has a 98% two-
year survival and wild-type TTR has a 100% two-year
survival (14). Death commonly results from progressive
heart failure or sudden cardiac death.
Clinical management and prognosis differ among
the different types of cardiac amyloidosis. A thorough
workup to distinguish AL amyloidosis from the TTR
type is imperative to prevent inappropriate treatment, like
chemotherapy for systemic AL amyloidosis.
Liver transplantation has been reported to halt the
progression of clinical manifestations of familial TTR
amyloidosis (15). Medical treatment focuses on alleviat-
ing the symptoms of heart failure and slow or stop
progressive amyloid deposition.
Amyloid infiltration in the heart impairs diastolic
filling, reducing stroke volume, leading to compensatory
Fig. 3. Inversion recovery images demonstrating late gado-
linium enhancement throughout the myocardium. Diffuse
inﬁltration of myocardium with amyloid results in tech-
nical difﬁculty in myocardial nulling. (A) In this case,
abnormal enhancement of the papillary muscle (arrow)
acts as a reference to normal myocardial relaxation time
on magnitude images. (B) Subsequent phase sensitive inver-
sion recovery images demonstrate the extent of myocardial
abnormality.
Transthyretin cardiac amyloidosis and heart failure
Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25500 - http://dx.doi.org/10.3402/jchimp.v4.25500 3
(page number not for citation purpose)tachycardia to preserve stroke volume. Beta blockers
should therefore be avoided (1). Optimization of fluid
status with diuretics is key in management. Calcium
channel blockers and digitalis are contraindicated in
cardiac amyloidosis because they bind to the amyloid
fibrils and have the potential of causing toxicity (1618).
Angiotensin receptor antagonists or converting enzyme
inhibitors may be beneficial in low doses to improve
cardiac output by reducing afterload, especially when
there is coexisting hypertension (1).
New treatments provide alternatives to liver transplant.
Diflunisal and tafamidis are medications that stabilize
transthyretin monomers, although the non-steroidal anti-
inflammatory properties of diflunisal make this medica-
tion less appealing for individuals with heart failure (19).
In addition, new drugs are in clinical trials to silence
the TTR gene, reducing production of this protein by the
liver (20).
Death usually results from intractable heart failure, or
sudden cardiac death due to the predisposition of these
patients to suffer ventricular dysrhythmias and conduc-
tion abnormalities. Implantable cardiacdefibrillators have
not been widely used in patients with amyloidosis (21).
It iswell known that implantable cardioverterdefibrillator
therapy improves survival in patients with cardiomyo-
pathy due to other etiologies, but its benefit in patients
with cardiac amyloidosis is unclear, and the consensus
opinion is that they do not prolong survival with cardiac
amyloidosis (22).
Conclusion
Hereditary TTR is an uncommonly recognized cause of
heart failure in the population and patients may wait
several years before an accurate diagnosis, leading to
additional significant and irreversible deterioration. Mis-
diagnosis is common due to misinterpreting LV infiltra-
tion as hypertensive heart disease or other entities that
produce ventricular thickening.
The patient presented had the diagnosis of non-
ischemic cardiomyopathy for several years and had been
treated multiple times in the past for volume overload
due to decompensated heart failure, but the etiology of
his cardiomyopathy was never established or probably
was attributed to his history of hypertension.
A high index of clinical suspicion for TTR is necessary
to make the diagnosis, especially when evaluating the
elderly African American/Caribbean population with
CHF and LV thickening without a clear etiology.
In summary, we should have a low threshold for inves-
tigativeworkupinthesepatientsduetothepromiseofnew
therapies for TTR and the positive impact that an early
diagnosis could have in the treatment and prognosis. In
addition, recognition of agenetic form of cardiomyopathy
may also help with recognition of amyloidosis among
relatives who carry the same genetic predisposition.
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